JP2017128569A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017128569A5 JP2017128569A5 JP2017009474A JP2017009474A JP2017128569A5 JP 2017128569 A5 JP2017128569 A5 JP 2017128569A5 JP 2017009474 A JP2017009474 A JP 2017009474A JP 2017009474 A JP2017009474 A JP 2017009474A JP 2017128569 A5 JP2017128569 A5 JP 2017128569A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- glibenclamide
- lyophilized
- lyophilized pharmaceutical
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 12
- 229960004580 glibenclamide Drugs 0.000 claims 9
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims 9
- 235000002639 sodium chloride Nutrition 0.000 claims 9
- 239000002585 base Substances 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 6
- 229930195725 Mannitol Natural products 0.000 claims 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims 6
- 239000000594 mannitol Substances 0.000 claims 6
- 235000010355 mannitol Nutrition 0.000 claims 6
- 229910052783 alkali metal Inorganic materials 0.000 claims 5
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- -1 alkali metal salt Chemical class 0.000 claims 4
- 235000000346 sugar Nutrition 0.000 claims 4
- 150000008163 sugars Chemical class 0.000 claims 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical class N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 3
- 150000001447 alkali salts Chemical class 0.000 claims 3
- 239000007864 aqueous solution Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 2
- 229930091371 Fructose Natural products 0.000 claims 2
- 239000005715 Fructose Substances 0.000 claims 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 2
- 229930006000 Sucrose Natural products 0.000 claims 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 2
- 150000001340 alkali metals Chemical class 0.000 claims 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229930182830 galactose Natural products 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 239000008101 lactose Substances 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 239000001103 potassium chloride Substances 0.000 claims 2
- 235000011164 potassium chloride Nutrition 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 239000000600 sorbitol Substances 0.000 claims 2
- 239000005720 sucrose Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 150000001342 alkaline earth metals Chemical class 0.000 claims 1
- 229910021529 ammonia Inorganic materials 0.000 claims 1
- 239000008367 deionised water Substances 0.000 claims 1
- 229910021641 deionized water Inorganic materials 0.000 claims 1
- 239000012153 distilled water Substances 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000002504 physiological saline solution Substances 0.000 claims 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims 1
- 159000000000 sodium salts Chemical group 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99224107P | 2007-12-04 | 2007-12-04 | |
| US60/992,241 | 2007-12-04 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015012350A Division JP6084639B2 (ja) | 2007-12-04 | 2015-01-26 | 凍結乾燥のための改良された処方物および方法ならびにそれによって提供される凍結乾燥物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018137703A Division JP6603762B2 (ja) | 2007-12-04 | 2018-07-23 | 凍結乾燥のための改良された処方物および方法ならびにそれによって提供される凍結乾燥物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017128569A JP2017128569A (ja) | 2017-07-27 |
| JP2017128569A5 true JP2017128569A5 (enExample) | 2017-09-07 |
| JP6377189B2 JP6377189B2 (ja) | 2018-08-22 |
Family
ID=40718143
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010537028A Expired - Fee Related JP5812318B2 (ja) | 2007-12-04 | 2008-12-03 | 凍結乾燥のための改良された処方物および方法ならびにそれによって提供される凍結乾燥物 |
| JP2015012350A Active JP6084639B2 (ja) | 2007-12-04 | 2015-01-26 | 凍結乾燥のための改良された処方物および方法ならびにそれによって提供される凍結乾燥物 |
| JP2017009474A Active JP6377189B2 (ja) | 2007-12-04 | 2017-01-23 | 凍結乾燥のための改良された処方物および方法ならびにそれによって提供される凍結乾燥物 |
| JP2018137703A Expired - Fee Related JP6603762B2 (ja) | 2007-12-04 | 2018-07-23 | 凍結乾燥のための改良された処方物および方法ならびにそれによって提供される凍結乾燥物 |
| JP2019153477A Active JP6866438B2 (ja) | 2007-12-04 | 2019-08-26 | 凍結乾燥のための改良された処方物および方法ならびにそれによって提供される凍結乾燥物 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010537028A Expired - Fee Related JP5812318B2 (ja) | 2007-12-04 | 2008-12-03 | 凍結乾燥のための改良された処方物および方法ならびにそれによって提供される凍結乾燥物 |
| JP2015012350A Active JP6084639B2 (ja) | 2007-12-04 | 2015-01-26 | 凍結乾燥のための改良された処方物および方法ならびにそれによって提供される凍結乾燥物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018137703A Expired - Fee Related JP6603762B2 (ja) | 2007-12-04 | 2018-07-23 | 凍結乾燥のための改良された処方物および方法ならびにそれによって提供される凍結乾燥物 |
| JP2019153477A Active JP6866438B2 (ja) | 2007-12-04 | 2019-08-26 | 凍結乾燥のための改良された処方物および方法ならびにそれによって提供される凍結乾燥物 |
Country Status (14)
| Country | Link |
|---|---|
| US (6) | US8277845B2 (enExample) |
| EP (2) | EP2868315B1 (enExample) |
| JP (5) | JP5812318B2 (enExample) |
| CN (1) | CN101932308B (enExample) |
| CA (3) | CA3123813C (enExample) |
| CY (1) | CY1119256T1 (enExample) |
| DK (1) | DK2868315T3 (enExample) |
| ES (1) | ES2638977T3 (enExample) |
| HR (1) | HRP20171223T1 (enExample) |
| LT (1) | LT2868315T (enExample) |
| PL (1) | PL2868315T3 (enExample) |
| PT (1) | PT2868315T (enExample) |
| SI (1) | SI2868315T1 (enExample) |
| WO (1) | WO2009073711A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3123813C (en) * | 2007-12-04 | 2024-10-08 | Remedy Pharmaceuticals, Inc. | IMPROVED GLIBENCLAMIDE FORMULATIONS AND RELATED FREEZE-DRYING METHODS, AND FREEZE-DRY SATE PRODUCED THUS |
| WO2009097443A2 (en) | 2008-01-29 | 2009-08-06 | Remedy Pharmaceuticals, Inc. | Liquid formulations of compounds active at sulfonylurea receptors |
| WO2013086292A1 (en) * | 2011-12-09 | 2013-06-13 | Enject, Inc. | Glucagon formulations |
| CN104602682B (zh) | 2012-05-08 | 2018-12-14 | 埃罗米克斯公司 | 用于治疗水通道蛋白介导的疾病的化合物 |
| ES2728782T3 (es) * | 2012-05-25 | 2019-10-28 | Univ California | Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN |
| US9155695B2 (en) | 2013-03-14 | 2015-10-13 | Medtronic, Inc. | Injectable ropinirole compositions and methods for making and using same |
| EP3065729A4 (en) | 2013-11-06 | 2017-05-31 | Aeromics, Inc. | Novel formulations |
| WO2015134906A1 (en) * | 2014-03-07 | 2015-09-11 | Endologix, Inc. | Forming hydrogels and materials therefor |
| TW201613888A (en) * | 2014-09-26 | 2016-04-16 | Helsinn Healthcare Sa | Crystalline forms of an NK-1 antagonist |
| CN108348567B (zh) | 2015-05-29 | 2022-03-01 | 马里兰州立大学巴尔的摩分校 | 减少或预防由内皮细胞的机械刺激所致的内膜损伤的方法 |
| KR20240105519A (ko) * | 2015-10-07 | 2024-07-05 | 레메디 파마슈티칼즈, 인크. | Cns 부종과 관련한 손상 또는 병태의 치료 방법 |
| US20170320862A1 (en) * | 2016-05-03 | 2017-11-09 | Cadila Healthcare Limited | Process for the preparation of brexpiprazole and intermediates thereof |
| JP7165648B2 (ja) | 2016-07-29 | 2022-11-04 | バイオジェン チェサピーク エルエルシー | Ｓｕｒ１－ｔｒｐｍ４チャネル阻害剤による医療処置方法 |
| CN108210501B (zh) * | 2016-12-14 | 2019-03-08 | 中国人民解放军军事医学科学院毒物药物研究所 | 一种磺酰脲类药物的注射用药物组合物及其制备方法 |
| KR102336425B1 (ko) | 2017-06-30 | 2021-12-07 | 무라다기카이가부시끼가이샤 | 반송 시스템 및 반송 방법 |
| CN108553428A (zh) * | 2018-05-29 | 2018-09-21 | 昆药集团股份有限公司 | 格列本脲制剂及其制备方法 |
| AR124337A1 (es) * | 2020-12-14 | 2023-03-15 | Concentric Analgesics Inc | Formulaciones farmacéuticas de un profármaco fenólico agonista del trpv1 |
| WO2022187567A2 (en) * | 2021-03-04 | 2022-09-09 | Biogen Chesapeake Llc | Low-sorbing glyburide formulation and methods |
| WO2022195118A1 (en) | 2021-03-19 | 2022-09-22 | Eligo Bioscience | Therapeutic use of engineered postbiotics comprising bacteriocins and/or endolysins for treating cutaneous lymphoma |
| CN113274361B (zh) * | 2021-06-08 | 2022-05-06 | 吉林津升制药有限公司 | 一种烟酰胺冻干粉针剂及其制备方法 |
| WO2023168379A1 (en) * | 2022-03-03 | 2023-09-07 | Biogen Chesapeake Llc | Low-sorbing glyburide kit, formulation and methods |
| WO2025087311A1 (zh) | 2023-10-24 | 2025-05-01 | 江苏恒瑞医药股份有限公司 | 一种磺酰脲类衍生物的药物组合物 |
| US12251389B1 (en) | 2024-04-22 | 2025-03-18 | Remedy Pharmaceuticals, Inc. | Methods of treating ischemic stroke at risk for cerebral or cerebellar edema |
| US12251388B1 (en) | 2024-05-09 | 2025-03-18 | Remedy Pharmaceuticals, Inc. | Methods of treating ischemic stroke at risk for cerebral or cerebellar edema |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4384975A (en) | 1980-06-13 | 1983-05-24 | Sandoz, Inc. | Process for preparation of microspheres |
| DE3833439A1 (de) | 1988-10-01 | 1991-09-12 | Hoechst Ag | Verfahren zur mikronisierung von glibenclamid |
| US5258185A (en) * | 1989-08-23 | 1993-11-02 | Bauer Kurt H | Highly active, rapidly absorbable formulations of glibenclamide, processes for the production thereof and their use |
| GB9003185D0 (en) * | 1990-02-13 | 1990-04-11 | Ici Plc | Pharmaceutical compositions |
| CA2127877A1 (en) | 1992-01-21 | 1993-07-22 | Robert M. Platz | Improved process for preparing micronized polypeptide drugs |
| IS1796B (is) | 1993-06-24 | 2001-12-31 | Ab Astra | Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband |
| AU685264B2 (en) | 1994-04-25 | 1998-01-15 | Kyowa Hakko Kogyo Co. Ltd. | Method for stabilizing compound dx-52-1 and lyophilized composition thereof |
| US5747002A (en) | 1995-04-05 | 1998-05-05 | Genentech, Inc. | Preparation of sodium chloride aerosol formulations |
| US5856360A (en) * | 1996-05-03 | 1999-01-05 | Children's Hospital Medical Center | Pharmaceutical method for the treatment of severe blood loss and for the inhibition or treatment of hemorrhagic shock |
| US5817343A (en) | 1996-05-14 | 1998-10-06 | Alkermes, Inc. | Method for fabricating polymer-based controlled-release devices |
| DE69729880T3 (de) * | 1996-12-24 | 2012-05-10 | Biogen Idec Ma Inc. | Stabile flüssige interferon-zubereitungen |
| US5859037A (en) | 1997-02-19 | 1999-01-12 | Warner-Lambert Company | Sulfonylurea-glitazone combinations for diabetes |
| SI0999826T1 (en) | 1997-07-29 | 2004-12-31 | Pharmacia & Upjohn Company | Self-emulsifying formulation for lipophilic compounds |
| US6056977A (en) | 1997-10-15 | 2000-05-02 | Edward Mendell Co., Inc. | Once-a-day controlled release sulfonylurea formulation |
| EE200000694A (et) * | 1998-05-29 | 2002-06-17 | Biogen, Inc. | Inimese rekombinantse iterferooni beeta-1a (IFN-ß-1a) formulatsioon |
| JP3956654B2 (ja) | 2000-06-29 | 2007-08-08 | 小野薬品工業株式会社 | Ｎ−［ｏ−（ｐ−ピバロイルオキシベンゼンスルホニルアミノ）ベンゾイル］グリシン・モノナトリウム塩・４水和物含有溶液および製剤 |
| US6552082B2 (en) | 2000-06-29 | 2003-04-22 | Ono Pharmaceutical Co., Ltd. | Solution of N-[o-(p-pivaloyloxybenzenesulfonylamino)benzoyl] glycine monosodium salt tetra-hydrate and drug product thereof |
| US20030175349A1 (en) | 2001-01-30 | 2003-09-18 | Council Of Scientific And Industrial Research | Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient |
| WO2002079778A2 (en) | 2001-03-28 | 2002-10-10 | Rheologics, Inc. | In vivo delivery methods and compositions |
| US20080220441A1 (en) | 2001-05-16 | 2008-09-11 | Birnbaum Eva R | Advanced drug development and manufacturing |
| US20030125338A1 (en) | 2001-06-12 | 2003-07-03 | Active Pass Pharmaceuticals, Inc. | Compounds, compositions and methods for modulating beta-amyloid production |
| MXPA04000324A (es) * | 2001-07-17 | 2004-07-23 | N Gene Res Lab Inc | Una combinacion farmaceutica sinergistica para la prevencion o tratamiento de diabetes. |
| ES2807274T3 (es) * | 2002-03-20 | 2021-02-22 | Univ Maryland | Un canal catiónico no selectivo en células neurales y compuestos que bloquean el canal para su uso en el tratamiento de la inflamación del cerebro |
| US8980952B2 (en) * | 2002-03-20 | 2015-03-17 | University Of Maryland, Baltimore | Methods for treating brain swelling with a compound that blocks a non-selective cation channel |
| DE10325989A1 (de) | 2003-06-07 | 2005-01-05 | Glatt Gmbh | Verfahren zur Herstellung von und daraus resultierende Mikropellets sowie deren Verwendung |
| GB0316237D0 (en) | 2003-07-11 | 2003-08-13 | Astrazeneca Ab | Therapeutic agents |
| DE10341414A1 (de) | 2003-09-05 | 2005-03-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Oral zu applizierende Darreichungsform für schwerlösliche saure und amphotere Wirkstoffe |
| US8673964B2 (en) | 2004-05-20 | 2014-03-18 | Diamedica Inc. | Use of drug combinations for treating insulin resistance |
| JP5085326B2 (ja) | 2004-09-18 | 2012-11-28 | ユニバーシティ オブ メリーランド，ボルチモア | ＮＣＣａ−ＡＴＰチャネルを標的とする処置剤およびその使用方法 |
| EP1853246A1 (en) | 2005-02-17 | 2007-11-14 | Instituto del Metabolismo Celular, S.L. | L-aspartic acid for the treatment of problems in connection with the fat or glucose metabolism |
| US7659281B2 (en) | 2006-04-25 | 2010-02-09 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors |
| EP2071917B1 (en) | 2006-09-29 | 2012-11-21 | Infa S.A. | Packaging system for pharmaceutical compositions and kit for intravenous administration |
| CA3123813C (en) * | 2007-12-04 | 2024-10-08 | Remedy Pharmaceuticals, Inc. | IMPROVED GLIBENCLAMIDE FORMULATIONS AND RELATED FREEZE-DRYING METHODS, AND FREEZE-DRY SATE PRODUCED THUS |
-
2008
- 2008-12-03 CA CA3123813A patent/CA3123813C/en active Active
- 2008-12-03 LT LTEP14188334.8T patent/LT2868315T/lt unknown
- 2008-12-03 US US12/746,164 patent/US8277845B2/en active Active
- 2008-12-03 DK DK14188334.8T patent/DK2868315T3/en active
- 2008-12-03 EP EP14188334.8A patent/EP2868315B1/en active Active
- 2008-12-03 JP JP2010537028A patent/JP5812318B2/ja not_active Expired - Fee Related
- 2008-12-03 CA CA2707484A patent/CA2707484C/en active Active
- 2008-12-03 WO PCT/US2008/085384 patent/WO2009073711A1/en not_active Ceased
- 2008-12-03 SI SI200831850T patent/SI2868315T1/sl unknown
- 2008-12-03 CN CN200880126038.6A patent/CN101932308B/zh active Active
- 2008-12-03 PT PT141883348T patent/PT2868315T/pt unknown
- 2008-12-03 PL PL14188334T patent/PL2868315T3/pl unknown
- 2008-12-03 EP EP08857974.3A patent/EP2224913B1/en active Active
- 2008-12-03 CA CA3240562A patent/CA3240562A1/en active Pending
- 2008-12-03 ES ES14188334.8T patent/ES2638977T3/es active Active
-
2012
- 2012-09-11 US US13/610,335 patent/US8858997B2/en active Active
-
2014
- 2014-10-07 US US14/508,488 patent/US10117834B2/en active Active
-
2015
- 2015-01-26 JP JP2015012350A patent/JP6084639B2/ja active Active
-
2017
- 2017-01-23 JP JP2017009474A patent/JP6377189B2/ja active Active
- 2017-08-09 HR HRP20171223TT patent/HRP20171223T1/hr unknown
- 2017-08-29 CY CY20171100905T patent/CY1119256T1/el unknown
-
2018
- 2018-07-23 JP JP2018137703A patent/JP6603762B2/ja not_active Expired - Fee Related
- 2018-09-21 US US16/138,173 patent/US10426729B2/en active Active
-
2019
- 2019-08-26 JP JP2019153477A patent/JP6866438B2/ja active Active
- 2019-09-27 US US16/585,255 patent/US10869835B2/en active Active
-
2020
- 2020-12-18 US US17/126,993 patent/US20210244669A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015134763A5 (enExample) | ||
| JP2011505424A5 (enExample) | ||
| JP2016530259A5 (enExample) | ||
| JP2002363097A5 (enExample) | ||
| AR077436A1 (es) | Composiciones farmaceuticas para el tratamiento del cancer y otras enfermedades o trastornos que contienen el 4-{[9-cloro-7-(2-fluoro-6-metoxifenil)-5h-pirimido-[5,4-d][2]benzacepin-2-il]amino}-2-metoxibenzoico, o una de sus sales farmaceuticamente aceptables. | |
| EA201991693A1 (ru) | Производное пиридина в качестве ингибитора ask1 и способ его получения и применения | |
| JP2016515561A5 (enExample) | ||
| JP2019504086A5 (enExample) | ||
| JP2010524963A5 (enExample) | ||
| HRP20200889T1 (hr) | Upotreba dugodjelujućih peptida glp-1 | |
| JP2013545745A5 (enExample) | ||
| HRP20191285T1 (hr) | Predlijekovi karbidopa i l-dopa te njihova uporaba za liječenje parkinsonove bolesti | |
| JP2014511847A5 (enExample) | ||
| JP2011513492A5 (enExample) | ||
| ES2381672T3 (es) | Preparación en solución acuosa que comprende un antibiótico aminoglicósido y bromfenaco | |
| JP2016503058A5 (enExample) | ||
| FI3484446T3 (fi) | Vasta-ainekoostumuksia | |
| HRP20201883T1 (hr) | Oralne i injekcijske formulacije tetraciklinskih spojeva | |
| JP2019521102A5 (enExample) | ||
| FI3817751T3 (fi) | Vedettömän natriumtiosulfaatin formulaatioita | |
| JP2017509623A5 (enExample) | ||
| JP2017516847A5 (enExample) | ||
| JP2013518036A5 (enExample) | ||
| JP2012525437A5 (enExample) | ||
| JP2018537514A5 (enExample) |